Summary of 2026 Helicobacter pylori Treatment Guidelines
Bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) for 14 days is now the universal first-line regimen for H. pylori eradication in adults, endorsed by all major North American and European consensus groups. 1
First-Line Treatment Recommendations
Preferred Empiric Regimen
Bismuth quadruple therapy for 14 days achieves >85% eradication rates even in regions with dual clarithromycin and metronidazole resistance, because bismuth synergizes with metronidazole to overcome resistance. 1
Standard dosing: Bismuth subsalicylate 262 mg (2 tablets) four times daily, tetracycline 500 mg four times daily, metronidazole 500 mg three-to-four times daily, plus a high-potency PPI twice daily. 2, 1
The Toronto Consensus, Maastricht V/Florence Consensus, and American College of Gastroenterology all endorse this as the preferred first-line option. 3, 1
Alternative First-Line Options
Rifabutin triple therapy (PPI + amoxicillin 1g three times daily + rifabutin 150 mg twice daily) for 14 days is an acceptable empiric alternative for patients without penicillin allergy, since rifabutin and amoxicillin resistance remain rare (<2%). 2, 1
Concomitant quadruple therapy (PPI + amoxicillin + metronidazole + clarithromycin) for 14 days may be used when bismuth is unavailable; recent U.S. data show 89.8% eradication rates. 1
When Clarithromycin Triple Therapy Is Permissible
Clarithromycin-based triple therapy (PPI + clarithromycin + amoxicillin) should only be used when ALL three conditions are met: (1) local clarithromycin resistance <15%, (2) local eradication rates with this regimen exceed 85%, and (3) the patient has never received a macrolide antibiotic. 1
This regimen is discouraged in most North American settings where clarithromycin resistance reaches 30%. 1
Critical Treatment Duration Change
All first-line and rescue regimens must be administered for 14 days—not 7-10 days—to maximize eradication success, reduce retreatment costs, and limit microbiome disruption. 1
The shift from 7-10 day courses reflects declining efficacy amid rising antibiotic resistance. 1
Proton Pump Inhibitor Selection
Preferred PPIs (by Potency)
Rabeprazole 20-40 mg twice daily is the most potent PPI (equivalent to 36 mg omeprazole). 2, 1
Esomeprazole 20-40 mg twice daily (equivalent to 32 mg omeprazole). 2, 1
Lansoprazole 30-45 mg twice daily (equivalent to 27 mg omeprazole). 2, 1
Omeprazole 40 mg twice daily is the least preferred acceptable option. 2, 1
PPI to Avoid
- Pantoprazole must be avoided because its acid-suppression potency is substantially lower (40 mg pantoprazole = only 9 mg omeprazole). 2
Administration Guidelines
- PPIs must be taken 30 minutes before meals on an empty stomach, and H₂-receptor antagonists (e.g., famotidine) must not be used concurrently. 1
Second-Line (Rescue) Therapy After First-Line Failure
Core Stewardship Principle
- Never reuse clarithromycin or levofloxacin if they were part of a failed regimen, because resistance develops in >90% of previously treated strains. 4, 1
After Clarithromycin-Containing First-Line Failure
Bismuth quadruple therapy for 14 days is the preferred rescue option, achieving 69.3% eradication in salvage settings. 4, 1
Levofloxacin triple therapy (PPI + amoxicillin + levofloxacin 500 mg daily) for 14 days is an alternative, but susceptibility testing is strongly advised because levofloxacin resistance in North America ranges from 18-24%. 4, 1
After Bismuth Quadruple or Metronidazole-Containing First-Line Failure
Levofloxacin triple therapy for 14 days is recommended, with susceptibility testing strongly considered before use. 4, 1
High-dose dual therapy (high-potency PPI 80 mg twice daily + amoxicillin 2-3 g daily divided 3-4 times) for 14 days achieves approximately 89% eradication in salvage settings. 4, 1
Third-Line (Salvage) Therapy After Two Failures
- Culture with antimicrobial susceptibility testing is strongly recommended after second-line failure to guide subsequent therapy, although availability may be limited in North America. 3, 4, 1
Empiric Options When Susceptibility Data Unavailable
High-dose dual therapy (PPI 80 mg twice daily + amoxicillin 2-3 g daily divided 3-4 times) for 14 days is a viable empiric third-line regimen. 4, 1
Tetracycline-levofloxacin quadruple therapy (PPI + bismuth + tetracycline + levofloxacin) for 14 days achieved 98% eradication versus 69% for levofloxacin-amoxicillin triple therapy in head-to-head trials. 4
Bismuth quadruple therapy for 14 days may be used if it has not been previously administered. 4, 1
Concomitant therapy (PPI + amoxicillin + metronidazole + clarithromycin) for 14 days is acceptable when dual clarithromycin/metronidazole resistance is high, although evidence for salvage use is limited. 3
Fourth-Line Therapy (After ≥3 Failures)
A rifabutin-containing regimen (PPI + amoxicillin + rifabutin 150-300 mg daily) for 14 days should be reserved for patients who have failed at least three prior regimens because of the risk of myelotoxicity. 3, 4, 2, 1
Resistance to rifabutin and amoxicillin remains rare (<2%). 4, 2, 1
Antibiotic Stewardship Principles
Never Reuse
Clarithromycin: Resistance develops in >90% of previously treated strains. 4, 1
Levofloxacin: Resistance emerges rapidly after exposure. 4, 1
May Reuse
Metronidazole may be reused only when combined with bismuth, as the synergistic effect overcomes in-vitro resistance. 3, 4, 1
Amoxicillin and tetracycline can be safely reused because resistance remains <5% in most regions. 4, 1
Special Populations
Penicillin-Allergic Patients
Bismuth quadruple therapy (tetracycline-metronidazole based) is the preferred first-line regimen for patients with confirmed penicillin allergy. 1
After first-line failure, referral for formal allergy testing is strongly advised because most reported penicillin allergies are not true IgE-mediated reactions. 3, 4, 1
If testing confirms no true allergy, amoxicillin-containing regimens can be used safely. 4
Diagnostic Testing Recommendations
Non-Invasive Testing
Urea breath testing is the preferred non-invasive method for detecting active infection, offering high sensitivity (88-95%) and specificity (95-100%). 5, 1, 6
Stool antigen testing is an acceptable alternative when urea breath testing is unavailable (sensitivity 94%, specificity 92%). 5, 1
Pre-Test Medication Management
- Proton-pump inhibitors must be stopped 1-2 weeks before urea breath, stool antigen, or biopsy-based testing to avoid false-negative results. 1
Confirmation of Eradication
A test-of-cure (urea breath test or stool antigen) performed 4-6 weeks after completion of therapy is mandatory. 4
Current practice shows only 50-64% of patients receive confirmation testing, which is suboptimal. 1, 7
Emerging Paradigm Shifts
Eradication Regardless of Symptoms
- Approximately 40% of current guidelines advise eradication of H. pylori infection regardless of symptom status once infection is confirmed, recognizing the condition as an infectious disease without proven host benefit. 1
Antibiotic Resistance as Primary Driver
Common Pitfalls to Avoid
Do not use 7-10 day regimens; 14 days is now the universal standard. 1
Do not employ clarithromycin empirically unless local resistance is documented <15% and the patient has never received a macrolide. 1
Do not use levofloxacin as a first-line agent; reserve it for rescue therapy after other regimens have failed. 1
Do not repeat the same antibiotic combination that previously failed. 3, 1
Do not use pantoprazole when higher-potency PPIs are available. 2, 1
Do not perform diagnostic testing without a plan to treat, as H. pylori gastritis is recognized as an infectious disease that should be eradicated when diagnosed. 1
Do not rely on serology alone for treatment decisions; confirm active infection with urea breath or stool antigen testing. 1